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In humans, postnatal steady-state hematopoiesis is mainly taking place 
in the bone marrow, which constitutes 4 % of the total body mass. Bone 
marrow is a soft highly vascular modified, semi-solid and gelatinous con-
nective tissue that is located in the medullary cavity. 
Bone marrow of human adults can macroscopically be further sub-
divided into red and yellow bone marrow. Whereas the first one mainly 
consists of hematopoietic tissue, the latter is characterized by the pres-
ence of fat cells which colors the bone marrow yellowish by the carot-
enoids in the intracellular fat droplets. Whereas in newborns the major-
ity of the bones consist of red bone marrow, during childhood and aging 
the red bone marrow, especially in the facial bones and the diaphysis of 
the long bones, is gradually replaced by fat cells.
Although in adults nearly half of the bone marrow consists of fat cells, at 
times of physiological stress such as bleedings, the fat cells can be replaced 
by hematopoietic tissue, showing that the bone marrow and the hematopoi-
etic system are highly flexible and respond to demands and external stimuli.
HEMATOPOIETIC STEM CELLS
The term “stem cell” was introduced into the scientific literature by the 
German biologist Ernst Haeckel in the second half of the 19th century 
(Haeckel, 1868). He used the term to describe fertilized eggs but also a uni-
cellular organism from which, in his eyes, all multicellular organisms origi-
nated. In 1877 Paul Ehrlich discovered that cells can be stained with aniline- 
derived dyes making it possible to distinguish between different kinds of 
leukocytes (Ehrlich, 1879) (Ramalho-Santos and Willenbring, 2007).
This knowledge divided the hematologic field into two parties. 
Followers of the dualistic model believed that there are two types of com-
mitted precursor cells: myeloid precursors which are located in the bone 
marrow and lymphatic precursor cells, which are hosted in the lymphoid 
organs, like spleen and lymph nodes. In contrast, followers of the uni-
tarian model presumed that one single cell exist, that could differentiate 
into all three lineages. In the early 20th century the Russian-American 
embryologist Alexander Maximow and others were the first to use the 
term ‚hematopoietic stem cell‘ and hypothesized that this primitive 
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hematopoietic stem cell could differentiate into all mature blood cells 
(Ramalho-Santos and Willenbring, 2007).
Nearly 50 years later experimental proof was provided for the exis-
tence of such a multipotent hematopoietic stem cell (HSC) by radiation 
experiments. Upon exposure of a lethal dose of radiation, mice could be 
rescued through intravenous injection of bone marrow cells of a donor 
mouse (Lorenz et  al., 1951) by cellular reconstitution of a new hemato-
poietic system (Ford et  al., 1956). Later, Till and McCulloch were able 
to show that numbers of colonies detected in host spleens were propor-
tional to the number of transplanted bone marrow cells and that these 
colonies consisted of myeloid and erythroid cells, thus developing the 
first quantitative stem cell assay (Till and Mc, 1961).
All these early landmark studies show that primitive hematopoietic 
cells, located in the bone marrow, can engraft and generate multi-lineage 
progenies in vivo. In line with this concept it is now well known that he-
matopoiesis is hierarchical organized with hematopoietic stem cells on 
the top, which are able to differentiate into all mature blood cell types. 
Hematopoietic stem cells furthermore have the ability to self-renew and 
can undergo symmetric cell division thereby expanding the pool of he-
matopoietic stem cells. There are cell-intrinsic as well as extrinsic mecha-
nisms that control this balance of self-renewal and differentiation.
EXTRINSIC REGULATION OF HEMATOPOIETIC 
STEM CELLS
The bone marrow provides a so-called hematopoietic stem cell niche, 
which is believed to be the local microenvironment influencing main-
tenance, quiescence, and self-renewal of hematopoietic stem cells 
(Morrison and Scadden, 2014).
Arguably the first molecular evidence for a niche that would support 
hematopoietic stem cell maintenance and self-renewal was generated in 
a mouse model overexpressing parathyroid hormone or parathyroid hor-
mone-related peptide, specifically in osteolineage cells. Overexpression of 
either protein resulted in an increased release of the Notch ligand Jagged 
1 by osteoclasts, which consequently increased the number of hematopoi-
etic stem cells in vivo. Furthermore, these HSC showed upregulation of 
the Notch1 intracellular domain (Calvi et al., 2003; Hoffman, 2018). 
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The discovery that murine hematopoietic stem cells are enriched in 
the CD150+CD45-CD41-  population made it possible to detect murine 
hematopoietic stem cells using immunohistochemical stainings of bone 
marrow sections by a two-color stain. This allowed mapping of murine 
hematopoietic stem cells to a perivascular niche in the bone marrow 
(Kiel et al., 2005). 
However, these new techniques also put the initial findings from Calvi 
et al. into perspective, because only a small subset of murine hematopoi-
etic stem cells was localized next to osteolineage cells, suggesting a more 
indirect effect of these cells on hematopoietic stem cells (Kiel et al., 2005). 
Nowadays, with the use of multi-photon microscopy, light sheet micros-
copy, and transgenic reporter animals it is possible to obtain images from 
the central cavity of the bone marrow and acquire spatial as well as tem-
poral information to track hematopoietic stem cells in the bone marrow. 
These techniques also allowed to show that different stem- and progen-
itor cells occupy various and specialized niches created by distinct cell 
types: whereas -in line with previous publications- hematopoietic stem 
cells were mapped to a perivascular niche, lymphoid progenitors were 
mapped to an endosteal niche (Ding and Morrison, 2013). Cells which 
are located next to blood vessels are of course putative candidates for be-
ing an integral part of the stem cell niche by producing factors essential 
for hematopoietic stem cells. Perivascular mesenchymal stromal cells 
are very heterogeneous and produce multiple factors important for he-
matopoietic stem cell maintenance, including SCF and CXCL12 (Ding 
and Morrison, 2013) (Sugiyama et al., 2006) (Mendez-Ferrer et al., 2010). 
Multiple lines of evidence show that endothelial cells are not only located 
next to hematopoietic stem cells (Kiel et al., 2005) but are also function-
ally important for maintenance of hematopoietic stem cells in vitro and in 
vivo. Conditional deletion of membrane-bound SCF in perivascular stro-
mal cells as well as endothelial cells resulted in a reduction of hematopoi-
etic stem cells (Ding et  al., 2012). Furthermore, endothelial cells exclu-
sively express E-selectin which regulates quiescence (Winkler et al., 2012). 
Next to mesenchymal and endothelial cells there is also growing evidence 
that bone marrow macrophages and megakaryocytes are relevant regula-
tors of stem cells, as well as adipocytes and neural cells (Hoffman, 2018). 
The number of different cellular and molecular components that de-
fine the niche, as well as the fact that there are probably different niches 
for different hematopoietic stem cells and progenitors, testify to the 
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dynamics and complexity of the interaction between hematopoietic stem 
cells and their niche. The fact that hematopoietic stem cells, in compar-
ison to other multipotent stem cells, cannot be sufficiently expanded in 
vitro without loss of function, suggests that unknown soluble or mem-
brane-bound factors essential for hematopoietic stem cells are missing 
(Morrison and Scadden, 2014). Additionally, there are still many inter-
esting niche-related questions which are of great scientific interest and 
of clinical importance. Does the niche contribute to the development of 
hematological malignancies? Do benign and leukemic stem cells use the 
same spatial niche? If not, is it possible to target niche cells which are 
only essential for leukemic stem cells? (Morrison and Scadden, 2014)
The growing field of niche-research will probably not only shed light 
on basic scientific questions but will potentially also discover new poten-
tial therapeutic targets for treating hematological malignancies.
INTRINSIC REGULATION OF SELF-RENEWAL AND 
DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS
Beyond external niche-derived stimuli, hematopoietic stem cells are also 
regulated through cell-intrinsic mechanisms, such as transcription fac-
tors or epigenetic proteins. Transcription factors are proteins which are 
directly binding to promoter, enhancer or silencer regions in the genome, 
thereby regulating the transcriptional activity of genes. Whereas accord-
ing to Gene Ontology the human genome contains 1.052 genes that be-
long to the class of transcription factors, Vaquerizas et. al. present a list 
of 1.391 manually curated  transcription factors (Vaquerizas et al., 2009). 
How many of these are real transcription factors remains unclear.  
Transcription factors have pleiotropic functions and thereby obtain 
various roles in different subsets of hematopoietic cells (Bodine, 2017). 
Furthermore, lineage-specific transcription factors are regulating each 
other antagonistically thereby providing intricate feedback loops (Orkin 
and Zon, 2008).
Of clinical interest is the fact that in many hematopoietic malignancies 
transcription factors are often dysregulated or mutated, as a single ge-
netic event or as part of translocations (Bodine, 2017; Orkin and Zon, 
2008). For example, MLL, RUNX1, TEL/ETV6, SCL/Tal1 and LMO2 
are important transcription factors for regulation of hematopoietic stem 
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cells, that are quite often rearranged through chromosomal transloca-
tions in leukemic patients. These translocations can either result in dys-
regulation or oncogenic fusion proteins  (Orkin and Zon, 2008). 
Beyond transcription factors epigenetic regulators play a key role in regu-
lating self-renewal and differentiation of hematopoietic stem cells. 
CHROMATIN AND EPIGENETICS
Although the genetic code of essentially all somatic cells is identical, the 
differentiation process of immature hematopoietic stem cells  towards 
differentiated blood cells is associated with massive changes in the 
transcriptome. This implies that next to gene regulation through basic 
 genetic elements like promoters and enhancers, alternative mechanisms 
exist which control gene expression. 
In 1942 the term epigenetics was introduced by the embryolo-
gist Conrad Waddington although with a slightly different meaning 
(Deichmann, 2016; Slack, 2002). In modern biology, the term epigenetic 
refers to mechanisms which regulate gene transcription without changes 
in the DNA sequence. The fact that epigenetic mechanisms regulate 
transcription on top of “classical genetics” is literally described with the 
ancient Greek prefix “epi” meaning “on top of”. Already before the word 
epigenetic was introduced, the cytologist Walther Flemming in 1879 es-
tablished the term “chromatin” for describing stainable structures in the 
nucleus of a cell during mitosis. Nowadays the word chromatin is used to 
describe the DNA with its associated proteins which mostly includes the 
basic histone proteins (Deichmann, 2016).  
The total length of the DNA of a single diploid human cell is two 
meters. For ensuring that this amount of DNA can be stored in the nu-
cleus with a diameter of only 6 µm, DNA is organized in a non-random, 
highly organized structure which include many DNA associated proteins 
(Alberts B, 2002).  The smallest unit of the chromatin, the nucleosomes, 
consists of 147 bps of double helix DNA, which is wrapped tightly around 
an octamer assembled of dimers of the core histone proteins (Luger et al., 
1997). The core histone proteins (H2A, H2B, H3 and H4) are highly evo-
lutionary conserved and consist of two functionally distinct domains- 
the globular domain and a protruding tail. The globular domains of all 
four core histones form the histone scaffold around which the DNA is 
CHAPTER 1
INTRODUCTION AND OUTLINE OF THE THESIS16
wrapped tightly around. The part of the globular domain which is in di-
rect contact with the DNA, is referred to as the “lateral surface”. Beyond 
this globular domain, all four highly basic core histone proteins have pro-
truding tails (Tropberger and Schneider, 2013).  Multiple nucleosomes 
are connected with each other through linker DNA and the linker his-
tone protein H1. Two different ground states of chromatin can be dis-
tinguished: hetero- and euchromatin. Heterochromatin contains mostly 
genes which are repressed. In contrast, euchromatin is more openly con-
figurated and thereby facilitates the binding of proteins of the transcrip-
tional machinery (Allis and Jenuwein, 2016).
Epigenetic mechanisms include all chemical or structural modifica-
tions of the chromatin that influence transcriptional activity (Deichmann, 
2016). Interestingly, some of these modifications are heritable so that cells 
can give a blueprint of their epigenome to their daughter cells (Heard and 
Martienssen, 2014). The majority of these modifications are reversible, ren-
dering epigenetic proteins potentially clinical relevant target structures. 
DNA METHYLATION
DNA methylation was one of the first epigenetic mechanisms which was 
identified. Although chemical modifications of DNA had already been 
detected in 1948 (Hotchkiss, 1948), the proof that methylation of cytosine 
repressed transcription of genes was provided in 1980 (Allis and Jenuwein, 
2016; Razin and Riggs, 1980). 
Methylation of cytosine residues occurs mainly if the cytosine is followed 
directly by guanine (CpG: cytosine-phosphate-guanine) (Esteller, 2008). 
CpGs are distributed across the genome in a nonrandom manner and oc-
cur in GC-rich regions, so-called CpG islands. These CpG islands are very 
often localized in gene-regulatory regions like promoters in proximity to the 
transcriptional start sites. CpG islands in healthy cells localized in these re-
gions are protected from DNA methylation, whereas CpG’ sites localized 
elsewhere in the genome are frequently methylated (Bird, 2002). 
The methylation of cytosine is catalyzed by three different DNA meth-
yltransferases (DNMT1, DNMT3A and DNMT3B). 
DNMT1 is a “maintenance” methyltransferase, establishing the methyl-
ation mark of the daughter strand after recognition of the methylated CpG 
site of the parent strand. In contrast to DNMT1, DNMT3A and DNMT3B 
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are predominantly de novo methyltransferases, which can methylate previ-
ous non-methylated cytosine residues (Bird, 2002; Rose and Klose, 2014). 
Interestingly, 75% of the methylome (the collection of methylated loci) 
is consistent across all cell types, whereas 25% were cell-type specific ei-
ther hyper- or hypomethylated (Liu et  al., 2016). Comparison of DNA 
methylation patterns of tumor cells in comparison to their healthy coun-
terparts have shown that DNA of cancer cells is globally less methy-
lated (Feinberg and Vogelstein, 1983). Differences in methylation pat-
terns can occur in promoter regions of oncogenes, which are either low 
or not expressed in healthy cells. Upon demethylation, these onco-
genes are expressed and can contribute to tumorigenesis (Esteller, 2008). 
Interestingly, increased demethylation has also been observed in regions 
containing repetitive DNA sequences (Feinberg and Tycko, 2004), such 
as peri-centromeric regions.  These might result in chromosomal insta-
bility and aneuploidy, which are both frequently observed in cancer cells 
(Esteller, 2008; Rodriguez et al., 2006). In line with this hypothesis, func-
tional knockout of cytosine DNA methyltransferases results in chromo-
somal instability in human cancer cells (Karpf and Matsui, 2005).
Although cancer cells show global demethylation, hypermethylation of 
promoter-regions located next to or in CpG islands can specifically silence 
tumor suppressor genes involved in cell cycle control (e.g. Rb) (Ohtani-
Fujita et  al., 1993), DNA-repair (e.g. BRCA1) (Zhang and Long, 2015) or 
apoptosis (e.g. Caspase 8) (Wu et  al., 2010). Hypermethylation of such 
CpG islands occurs in a cancer-type specific way (Costello et al., 2000).
The fact that malignant cells show massive aberrations of the methy-
lome in comparison to their healthy counterparts, suggests that overex-
pression, abnormal recruitment or mutations in genes coding for DNA-
methyltransferases might contribute to cancerogenesis. Overexpression of 
DNMT1, DNMT3A and DNMT3B methyltransferases was found in a va-
riety of malignant diseases like AML (Mizuno et al., 2001). Furthermore, 
mutations in DNMT1, DNMT3A and DNMT3B can be detected in differ-
ent cancer subtypes. Whereas mutations in DNMT1 are most frequently 
found in colon cancer cells (Kanai et  al., 2003), is DNMT3A often mu-
tated in hematological diseases like acute myeloid leukemia (Ley et al., 
2010), myeloid dysplastic syndrome (Haferlach et  al., 2014) and acute 
lymphatic leukemia (Neumann et al., 2013).
Indeed, DNMT3A is the most frequently mutated epigenetic modifier 
in AML with a frequency of 6 to 36% (Cancer Genome Atlas Research 
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et  al., 2013; Wouters and Delwel, 2015). Almost 50 % of DNMT3A mu-
tations in AML patients occur in a DNA base triplet coding for argi-
nine-882, leading to an amino acid exchange to histidine (R882H) or 
cysteine (R882C) within the catalytic domain, resulting in a missense 
mutation. AML cells overexpressing R882H protein show a ca. 80% re-
duced methyltransferase activity in comparison to the wild-type, sug-
gesting a dominant negative phenotype (Russler-Germain et  al., 2014). 
In line with these results conditional knockout studies in murine he-
matopoietic stem cells show that loss of DNMT3A results in increased 
self-renewal of hematopoietic stem cells and hampered differentiation 
(Challen et al., 2012).
The first hint that DNMT3A mutations are early events in the multi-
step model of leukemogenesis arose after deep-sequencing analysis of 
different hematopoietic subsets in AML patients harboring mutations 
in DNMT3A and NPMI1. Whereas both mutations could be detected 
in AML blasts, only DNMT3A mutations were detectable in the most 
primitive hematopoietic compartment, including hematopoietic stem 
cells and multipotent progenitors. Xenotransplantation of non-leukemic 
DNMT3Amut immunophenotypic hematopoietic stem cells in immu-
nodeficient mice resulted in multilineage differentiation, indicating that 
these cells are fully functional hematopoietic stem cells. Furthermore, 
these cells showed a repopulation advantage over wild-type hematopoi-
etic stem cells in xenotransplantation assays, suggesting that hematopoi-
etic stem cells harboring DNMT3A mutations have more self-renewal 
and can be considered as pre-leukemic stem cells. Interestingly, CD33+ 
cells in the peripheral blood of patients in remission showed exclusively 
expression of mutated DNMT3A, but not expression of the mutated 
NPM1 allele (Shlush et  al., 2014). This shows that DNMT3Amut hema-
topoietic stem cells are capable of escaping the classical cytotoxic chemo-
therapy and thereby represent a pool of expanded stem cells which might 
acquire secondary mutations resulting in a relapse of the disease. In line 
with these results, DNMT3A R882H mediates resistance to anthracyclines 
(Guryanova et al., 2016), a drug class which is an essential part of the in-
duction therapy of acute myeloid leukemia (Yates et al., 1973). In general, 
are AML patients harboring a DNMT3A mutation at diagnosis older, 
have higher white blood cell counts and a worse outcome (Ley et al., 2010).
Because hypermethylation of CpG islands in promoter regions can 
be the consequence of dysfunction of DNA methyltransferases, but may 
119
also be due to reduced DNA demethylation, dysregulation or muta-
tions in genes coding for these enzymes appear to be causally involved in 
AML pathogenesis. Demethylation of 5-methylcytosine can occur during 
mitosis, when DNMT1 fails to copy the methyl group from the parent 
strand. DNMT1 can sense methylated and non-methylated cytosine but 
not 5-hydroxymethylcytosine, which is an intermediate product of the 
passive DNA demethylation process. 5-hydroxymethylcytosine can then 
be replaced by cytosine through the base excision repair pathway (Chan 
and Majeti, 2013). The conversion of 5-methylcytosine towards 5-hy-
droxymethylcytosine is mediated through three enzymes TET1, TET2 
and TET3 (Ko et al., 2010). Especially TET2 mutations can be found in 
a variety of myeloid malignancies like myelodysplastic syndrome, acute 
myeloid leukemia, chronic myelomonocytic leukemia and systemic 
mastocytosis (Delhommeau et  al., 2009; Tefferi et  al., 2009). The vast 
majority of these mutations is heterozygous and results in a dysfunc-
tional enzyme (Delhommeau et al., 2009). In line with this, conditional 
TET2 knockout mice display hematopoietic stem cells with increased 
self-renewal activity and furthermore show common features of myelop-
roliferative syndromes like monocytosis, splenomegaly and extramedul-
lary hematopoiesis (Moran-Crusio et al., 2011).
Additionally, whole-genome and exome-sequencing studies showed 
that mutations in IDH1 and IDH2 can be detected in 15% of all AML 
patients (Cancer Genome Atlas Research et al., 2013; Chan and Majeti, 
2013). Similar to mutations in DNMT3A, mutations in IDH are hetero-
zygous and occur at different hotspots in highly conserved arginine res-
idues, namely IDH1 R132, IDH2 R140 and IDH2 R172 (Chan and Majeti, 
2013). The mutant protein catalyzes the conversion of alpha-ketogluta-
rate to D-2-hydroxyglutarate under the consumption of NADPH. This 
results in aberrantly high levels of 2-hydroxyglutarate and a competi-
tive inhibition of multiple alpha-ketogluterate dependent dioxygenases 
like TET2 (Gross et al., 2010).  The fact that IDH and TET2 mutations 
are mutually exclusive and that both have highly similar hypermethyla-
tion signatures strongly suggests that IDH2 mutations mainly function 
through TET2 inhibition (Chan and Majeti, 2013).
The fact that so many genes that are directly or indirectly involved in 
DNA methylation are mutated in hematological malignancies, clearly 
indicate that aberrant DNA-methylation is a crucial step in malignant 
transformation of hematopoietic cells. 
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POST-TRANSLATIONAL MODIFICATIONS OF HISTONE 
PROTEINS
Histone proteins can undergo a plethora of different post-transla-
tional covalent modifications including acetylation, methylation, 
SUMOylation, citrullination, phosphorylation and ribosylation. Such 
modifications are mainly covalently bound to lysine (K), but can also be 
added to other amino acids like arginine, serine or threonine (Rothbart 
and Strahl, 2014). Proteins involved in post-translational modifications 
can be functionally subdivided into writers (proteins which establish the 
mark), readers (proteins which can recognize the histone mark) and eras-
ers (proteins which can remove the mark) (Zhang et al., 2015). 
So far, the best studied modifications are located on the protruding 
tail of the histone proteins. These covalent modifications are easily ac-
cessible for writers, erasers and readers and thereby influence transcrip-
tion, replication and DNA repair (Tropberger and Schneider, 2013). 
Post-translational modifications of histone tails are affecting the degree 
of compaction of chromatin regions, either directly by changing his-
tone-DNA or histone-histone interactions, or indirectly by recruitment 
of effector proteins (Cosgrove et  al., 2004; Rothbart and Strahl, 2014). 
Through integrative analysis of transcriptome and Chip-seq data it has 
become possible to associate different post-translational modifications of 
histone tails with different transcriptional states.
For example, H3K27ac and H3K4me1 mark active enhancers 
(Creyghton et  al., 2010; Zhang et  al., 2015). Accordingly, actively tran-
scribed genes are marked with H3K4me3 and acetylation of H3 and H4 
in promoter regions (Barrera et al., 2008; Deckert and Struhl, 2001; Liang 
et  al., 2004). Furthermore, actively transcribed genes are marked with 
H3K79me3 (Ng et al., 2003), H2BK120ub (Batta et al., 2011), H3K36me3 
(Pokholok et al., 2005) and acetylated H3 and H4 in the gene body (Myers 
et al., 2001) (Zhang et al., 2015). 
Different mass spectrometry approaches targeted to histone proteins 
have shown that up to seven post-translational modifications can be 
added to the N-terminal region of histone 3 (H31-50). Interestingly, spe-
cific combinations of different modifications were found more frequently 
than others (Young et al., 2009). This suggests that some modifications 
facilitate or prevent other modifications through crosstalk to other epi-
genetic pathways. Because nucleosomes contain homodimers of histone 
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proteins, it remains elusive if crosstalks between different pathways can 
only occur on one single histone polypeptide (symmetrically) or adjacent 
polypeptides (asymmetrically) (Rothbart and Strahl, 2014). 
Voigt et  al. showed via an MS approach with custom-made antibod-
ies against H3K27me2, H3K27me3, H4K20me1, that H3 and H4 dimers 
are not always modified in the same pattern (Rothbart and Strahl, 2014; 
Voigt et  al., 2012). These data, of course, leave a lot of room for specu-
lations and suggest that different epigenetic marks may influence each 
other even if they are located on different histone tails. 
Besides multiple publications focusing on post-translational modifi-
cations of histone tails, mass spectrometry experiments have shown that 
histone proteins can also undergo post-translational modifications of the 
globular domain. The most prominent of these post-translational mod-
ifications is located on the lateral surface and thereby affects residues 
of the protein which directly interact with DNA (Cosgrove et al., 2004; 
Tropberger and Schneider, 2013). These modifications can directly reg-
ulate accessibility without recruitment of further effector proteins by 
influencing mobility and stability of nucleosomes and DNA-histone in-
teractions  (Rothbart and Strahl, 2014; Tropberger and Schneider, 2013). 
So far, there are hardly any epigenetic reader proteins described as bind-
ing partners of post-translational modifications of the lateral surface 
(Tropberger and Schneider, 2013; Yu et al., 2012).
In contrast, many epigenetic reader, writer and eraser proteins have 
been described to post-translationally modify histone tails. One of the 
best-studied post-translational modifications of histones is acetylation. 
Enzymes transferring acetyl groups to lysine residues of histone proteins 
are called histone acetyltransferases (HAT), whereas enzymes removing 
acetyl groups are called histone deacetylases (HDAC) (Greenblatt and 
Nimer, 2014; Haberland et  al., 2009). Because dense chromatin states 
are to some degree the resultant of electrostatic attraction of positively 
charged histone proteins and negatively charged phosphate groups of the 
DNA, neutralization of the positive charge of histones through covalent 
binding of a negatively charged acetyl group results in loss of dense chro-
matin states. The dynamic balance of acetylated and histone proteins is 
antagonistically controlled by these two prominent families of histone- 
modifying enzymes (Haberland et al., 2009).  
Acetylated lysine residues, as described above, are in general associ-
ated with actively transcribed chromatin regions. Of note, mutations or 
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transcriptional dysregulation of histone acetyltransferases are linked to 
several malignant hematological diseases. For example 18% of all relapsed 
acute lymphatic leukemia patients present with a mutation in the acet-
yltransferase CREBBP (Greenblatt and Nimer, 2014). The overwhelming 
majority (89%) of mutations in CREBBP detected in highly hyperdiploid 
acute lymphoblastic leukemia patient samples is located in the functional 
histone acetyltransferase domain (Inthal et al., 2012). Functionally, these 
mutations result in impaired histone acetylation of H3K18 and transcrip-
tional dysregulation of CREBBP-target genes (Mullighan et al., 2011).  
Histone deacetylases have also shown to be involved in regulation of 
cell proliferation and cancer. Chip-seq experiments in murine embryonic 
stem cells showed that HDAC1 directly represses the tumor suppressor 
gene CDKN1A (Zupkovitz et al., 2010). Equivalent results were obtained 
through knockdown of HDAC2 in HeLa cells which resulted in CDKN1A 
upregulation and morphological signs of differentiation (Huang et  al., 
2005), suggesting that different family members of HDACs have at least 
to some degree overlapping functions. 
Histone deacetylases also play a role in the development of malignant he-
matological diseases. Expression of the fusion protein PML-RARalpha in 
acute promyelocytic leukemia cells results in aberrant recruitment of histone 
deacetylases to gene and promoter regions (Grignani et al., 1998; Tambaro 
et al., 2010). Similar results were obtained for the oncogenic fusion- protein 
RUNX1-ETO, which is able to bind HDAC1-3 (Amann et al., 2001). 
In contrast to acetylation of histone proteins, the transfer of methyl 
groups to histone proteins is associated with distinct transcriptional 
states, dependent on the localization and the number of methyl groups. 
Whereas H3K9me3 and H3K27me3 are involved by transcriptional repres-
sion, H3K4me3 is associated with transcriptionally active genes. Because, 
in contrast to acetylation, histone methylation does not result in physical 
changes, effector proteins are necessary to translate methylation patterns in 
corresponding transcriptional and chromatin changes. 
There is increasing evidence that enzymes that were once believed to 
only acetylate or methylate histone proteins, in fact are also able to mod-
ify non-histone proteins and thereby to alter their functional activity. 
This includes especially the tumor suppressor p53 (Tang et al., 2008), but 
also a key regulator of hematopoietic stem cells like RUNX1 (Yamaguchi 
et al., 2004).
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EPIGENETIC DRUGS AND THERAPIES IN MALIGNANT 
DISEASES
As described in the previous paragraphs, epigenetic changes due to mu-
tations or dysregulation of genes coding for epigenetic readers, writers, 
or erasers, are frequently observed in cancer cells. Because epigenetic 
changes like DNA-methylation or post-translational covalent histone 
modifications in general are reversible, these are quite attractive putative 
pharmacological targets (Greenblatt and Nimer, 2014).
The first example of a successful epigenetic therapy was provided by 
the use of drugs inhibiting DNA methyltransferases, like 5- azanucleoside 
(= 5-azacytidine, Vidaza®) and decitabine (= 5-aza-2’-deoxycytidine, 
Dakogen®) in acute myeloid leukemia and myelodysplastic syndrome (Jones 
et al., 2016). Whereas 5-azanucleoside can be incorporated into DNA as well 
as RNA (Navada et al., 2014), its 2’-deoxy-derivate decitabine can only be in-
corporated into DNA. In the 1960‘s these drugs were initially tested as cytar-
abine analogues and antimetabolites in clinical trials using high doses, with-
out resounding success due to their toxicity profiles (Cruijsen et al., 2014; 
Jones et al., 2016). Later, the two drugs received further attention after it was 
shown that their use at lower doses induces cellular differentiation and de-
methylation of DNA in embryonic cells (Jones and Taylor, 1980). 
The demethylating effect of 5-azacytidine is not due to direct de-
methylation of DNA, but through incorporation into the DNA during 
DNA replication and subsequent irreversible binding to and degrada-
tion of DNMT1 (Juttermann et  al., 1994). In line with these data, can-
cer cells treated with demethylating agents show demethylation of some 
tumor suppressor genes like p15/INK4B (Daskalakis et al., 2002) (Jones 
et al., 2016). After demonstrating their efficiency in multiple clinical tri-
als (Fenaux et al., 2009; Lubbert et al., 2016) both drugs were approved 
by the European Medicines Agency (EMA) and the Food and Drug 
Administration (FDA) for the treatment of myelodysplastic syndrome. 
Furthermore, 5-azacytidine is approved by EMA for the treatment of 
chronic myelomonocytic leukemia (CMML) and AML in older patients, 
who are not eligible for standard induction chemotherapy and decitabine 
is approved for the treatment of secondary AML patients, who are not 
eligible for conventional therapy. 
The toxicity profiles of both substances at lower doses are more ac-
ceptable so that especially older people, whose general and medical 
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conditions are more frequently not sufficient for classical induction cy-
totoxic chemotherapy regimens, are benefitting from epigenetic therapy 
approaches using 5-azacytidine and decitabine. This is especially im-
portant because more than 60% of all newly diagnosed AML patients 
are older than 60 years (National Cancer Institute, 2013). Interestingly, 
DNMT3Amut and TET2mut  MDS patients have a statistically signifi-
cant better response and progression-free survival to demethylating 
therapy approaches (Traina et  al., 2014), suggesting that cancer cells 
with mutations in genes coding for proteins involved in DNA methyl-
ation are more sensitive to demethylating agents. As mentioned above, 
mutations in IDH2 are observed in ca. 15% of all AML patients. In 2017 
the first IDH2 inhibitor, Enasidenib, was approved for the treatment 
of relapsed or refractory IDH2mut AML. The approval was the conse-
quence of impressive data of a phase I/II single arm multicenter study 
showing that after a median follow-up of 6,6 months 19% of all AML 
IDH2mut patients experienced a complete remission which lasted at me-
dian 8,2 months (FDA, 2017).
The largest group of epigenetic drugs being tested and approved by FDA 
or EMA represent inhibitors of enzymes involved in post- translational 
modifications of histone tails. 
Histone deacetylase-Inhibitors (HDACi) were initially discovered in 
drug screens aimed to search for differentiation inducers in leukemias 
(Jones et al., 2016; Richon et al., 1998). In line with the observation that 
HDACs are abnormally recruited through the fusion oncogenes AML1-
ETO and PML-RARalpha, exposure of AML cells harboring these trans-
locations to histone deacetylase inhibitors (HDACi) induces apoptosis 
and terminal differentiation (Insinga et  al., 2004; West and Johnstone, 
2014). Because the catalytic active domain of 11 of the 18 different HDACs 
in mammals  is highly conserved and because the majority of the HDACs 
have functional redundancy, many HDACi show activity against multi-
ple HDACs (Haberland et al., 2009; Halsall and Turner, 2016). 
In 2006 the first HDACi, Vorinostat, which showed activity against 
class I, IIa, IIb and IV HDACs, was approved for the treatment of cuta-
neous and peripheral T-cell lymphoma (Halsall and Turner, 2016). In the 
meanwhile, also Belinostat and Romidepsin have been approved for the 
same indications (Jones et  al., 2016). Recently, the histone- deacetylase 
inhibitor Panobinostat was approved for the treatment of multiple my-
eloma, in combination with the proteasome inhibitor Bortezomib (Jones 
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et al., 2016). Next to these already approved indications, HDACi are also 
tested in preclinical and early-clinical studies in other malignant diseases. 
Activating mutations in the H3K27 methyltransferase EZH2, part of 
catalytic subunit of the Polycomb Repressive Complex 2, can be detected 
in diffuse large B-cell lymphoma (DLCBL) and follicular lymphomas, 
and result in increased H3K27me3 due to altered substrate preferences. 
The EZH2 inhibitor GSK126 decreased H3K27me3 levels, which was asso-
ciated with an inhibition of proliferation, especially in EZH2mut DLCBL 
cell lines as well as in DLCBL xenografts (McCabe et al., 2012). The EZH2 
inhibitor Tazemostat was recently tested in heavily pretreated, relapsed 
and refractory follicular and diffuse large B-cell lymphoma patients. The 
overall response rate of patients suffering from EZH2mut follicular lym-
phoma was very high (92%), in contrast to EZH2wt follicular lymphoma 
patients. Similar to follicular lymphoma patients, also diffuse large 
B-cell lymphoma patients benefitted from the use of Tazemostat: 29% of 
the EZH2mut patients showed an overall response, whereas only 15% of 
EZH2wt patients did so. Fortunately, the drug was very well tolerated and 
showed a favorable side effect profile (Morschhauser F, 2017).   
Beyond single epigenetic agents, more and more combinational ther-
apeutic approaches are being tested. Because methylated DNA is fre-
quently associated with other repressive histone marks, such as deacetyl-
ated histones (Eden et  al., 1998; Jones et  al., 2016), the combinatorial 
use of HDACi and demethylating agents might be beneficial. In line 
with this hypothesis, exposure of colon carcinoma cells to the histone 
deacetylase inhibitor TSA upon pretreatment of  5-azacytidine results 
in re-expression of CDKN2A, whereas their use as single agents cannot 
re-express CDKN2A robustly (Cameron et al., 1999; Jones et al., 2016). In 
2014 data from a randomized study showed that the combination ther-
apy of Entinostat and 5-azacytidine in AML and MDS patients resulted 
in a lower median overall survival. Curiously, this combination therapy 
resulted in less demethylation leading the authors of this study to pro-
pose eventually antagonistic effects (Prebet et al., 2014). Next to testing 
drug combinations of only selective epigenetic agents, more and more 
regimes are explored which combine the use of classic cytotoxic agents 
with these epigenetic drugs. The rationale behind this approach is that in 
some cancer cells pre-exposure to demethylating agents like decitabine or 
5-azacitidine results in reduced resistance to classical cytotoxic chemo-
therapeutic drugs. For example, preclinical studies in platinum-resistant 
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ovarian cancer cells showed that exposure of decitabine to these cells re-
stores their sensitivity against platinum-based cytotoxic therapeutic ap-
proaches (Li et al., 2009). Supporting this hypothesis, a phase two trial of 
heavily-pretreated carboplatin-resistant ovarian cancer patients of treat-
ment with decitabine and carboplatin showed a very good response and 
progression-free survival (Matei et al., 2012).
The beneficial effect of the combinatorial use of epigenetic drugs and 
checkpoint inhibitors was accidentally discovered in a study which en-
rolled advanced treatment-refractory non-small lung cancer patients for 
testing the immune checkpoint inhibitor anti PD-1. Five out of 6 patients, 
who participated in a previous trial for testing the efficiency of the com-
binatorial use of azacytidine and Entinostat, showed no signs of any dis-
ease progression in six months (Juergens et al., 2011; Wrangle et al., 2013). 
In conclusion, the previous paragraphs show that the increased knowl-
edge in basic epigenetic science is more and more translated in clinical 
applications for treatment of cancer patients. In the next decades the 
epigenetic treatment options for patients with malignant diseases will 
increase.
OUTLINE OF THE THESIS
The overall aim of the research described in this thesis project was to 
unravel the role of human CBX-2, 4, 6, 7 and 8 proteins, in regulating 
normal human hematopoietic stem and progenitor cells and to explore 
whether (one of) these proteins could potentially be a therapeutic target 
in leukemia.  
Chapter 1 provides an introduction to hematopoiesis and hematopoi-
etic stem cells. Furthermore, we describe briefly the concept of the he-
matopoietic stem cell niche, their molecular and cellular components, 
and how the niche contributes to hemostasis of hematopoietic stem 
cells as one example of extrinsic regulation of hematopoietic stem cells. 
Furthermore, we give a short overview of transcription factors as one 
class of intrinsic hematopoietic stem cell regulators. The predominant 
part of the introduction will provide an overview about epigenetics, their 
role in cancerogenesis and epigenetic therapeutical approaches. 
Chapter 2 introduces the reader to characteristics of the aged hema-
topoietic system and hematopoietic stem cells. We discuss potential 
127
mechanisms that may contribute to hematopoietic stem cell (HSC) aging, 
and elude to the reversebility of aging associated changes in old HSCs. 
Chapter 3 gives a broad overview of Polycomb proteins and their role 
in the development of the hematopoietic system, cancerogenesis and dis-
cuss a potential role in aging.
In Chapter 4 we studied the function of different human CBX pro-
teins in regulating hematopoietic stem and progenitor cells by enforced 
overexpression of human CBX2, 4, 6, 7 and 8 in human CD34+ cord blood 
cells. We show that in vitro overexpression of human CBX7 has the most 
profound effect on self-renewal of primitive human CD34+ cord blood 
cells. Furthermore, we show that xenotransplantation of human CD34+ 
cord blood cells overexpressing CBX7 results in higher engraftment, en-
hanced myelopoiesis and increased self-renewal of huCD34+CD38- cells. 
Furthermore, we performed RNA-seq and Chip-seq of CBX7 overexpress-
ing CD34+ cord blood cells to identify direct targets of huCBX7.
We assessed expression levels of CBX7 in AML and performed 
knockdown experiments of CBX7 in two AML cells. In both cell lines 
knockdown of CBX7 was associated with an inhibition of proliferation. 
Additionally, knockdown of CBX7 in the HL60 cell line induced upregu-
lation of CD11b and morphological signs of differentiation. Besides that, 
knockdown of CBX7 in OCI-AML3 cells results in upregulation of CD14.
Furthermore, we identified novel interaction partners of human CBX 
proteins via a mass spectrometry approach in CBX7 overexpressing hu-
man and murine cells. We identified multiple H3K9-methyltransferase as 
binding partners of huCBX7. All of these three H3K9 methyltransferases 
have at least one tri-methylated lysine. Motif search of these trimeth-
ylated peptides revealed a sequence motif highly similar to H3K9me3 
and H3K27me3. Chip-Seq experiments for H3K9me3 and CBX7 showed 
that ca. 1/3 of all CBX7 peaks are associated with H3K9me3 peaks. 
Furthermore, we show that knockdown of SETDB1, one of the H3K9 
trimethylating enzymes, results in upregulation of CD11b and CD14 in 
HL60 and OCI-AML3 cells as well as inhibition of proliferation.
In Chapter 5 we summarize the findings and discuss future 
perspectives.
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